Zosano Pharma Corp Retained Earnings
Zosano Pharma Corp had Retained Earnings of -$395.52 million as of 2022-03-31, per its 10-Q filed 2022-05-13.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2022-05-13
- 2022-03-31: Retained Earnings (Accumulated Deficit) -$395.52M.
- 2021-12-31: Retained Earnings (Accumulated Deficit) -$362.12M.
- 2021-09-30: Retained Earnings (Accumulated Deficit) -$355.14M.
- 2021-06-30: Retained Earnings (Accumulated Deficit) -$346.48M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2022-03-31 | -$395.52M 10-Q · filed 2022-05-13 |
| 2021-12-31 | -$362.12M 10-Q · filed 2022-05-13 |
| 2021-09-30 | -$355.14M 10-Q · filed 2021-11-10 |
| 2021-06-30 | -$346.48M 10-Q · filed 2021-08-10 |
| 2021-03-31 | -$340.33M 10-Q · filed 2021-05-12 |
| 2020-12-31 | -$332.19M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$324.09M 10-Q · filed 2020-11-13 |
| 2020-06-30 | -$315.40M 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$307.51M 10-Q · filed 2020-05-14 |
| 2019-12-31 | -$298.82M 10-K · filed 2021-03-11 |
| 2019-09-30 | -$289.88M 10-Q · filed 2019-11-14 |
| 2019-06-30 | -$280.02M 10-Q · filed 2019-08-14 |
| 2019-03-31 | -$270.66M 10-Q · filed 2019-05-14 |
| 2018-12-31 | -$261.23M 10-K · filed 2020-03-13 |
| 2018-09-30 | -$251.09M 10-Q · filed 2018-11-15 |
| 2018-06-30 | -$242.92M 10-Q · filed 2018-08-09 |
| 2018-03-31 | -$234.08M 10-Q · filed 2018-05-15 |
| 2017-12-31 | -$225.87M 10-K · filed 2019-03-25 |
| 2017-09-30 | -$218.38M 10-Q · filed 2017-11-09 |
| 2017-06-30 | -$210.51M 10-Q · filed 2017-08-10 |
| 2017-03-31 | -$203.77M 10-Q · filed 2017-05-09 |
| 2016-12-31 | -$196.77M 10-K · filed 2018-03-12 |
| 2016-09-30 | -$188.97M 10-Q · filed 2016-11-09 |
| 2016-06-30 | -$181.53M 10-Q · filed 2016-08-10 |
| 2016-03-31 | -$175.01M 10-Q · filed 2016-05-12 |
| 2015-12-31 | -$166.89M 10-K · filed 2017-03-01 |
| 2015-09-30 | -$159.25M 10-Q · filed 2015-11-10 |
| 2015-06-30 | -$150.63M 10-Q · filed 2015-08-13 |
| 2015-03-31 | -$143.05M 10-Q · filed 2015-05-12 |
| 2014-12-31 | -$138.46M 10-K · filed 2016-03-29 |